Larchmont, NY – A new study evaluates an artificial intelligence (AI)-based algorithm for autocontouring prior to radiotherapy in head and neck cancer. Manual contouring to pinpoint the area of treatment requires significant time, and an AI algorithm to enable autocontouring has been introduced. The study is published in the peer-reviewed journal...
Latest News
The Journal of Blood Medicine has recently published data evaluating treatment options for haemophilia A. The publication reported in an indirect comparison that individualised prophylaxis with Elocta® (rFVIIIFc-efmoroctog alfa) is more efficacious than Hemlibra™ (emicizumab) administered every four weeks, and at least as effective as more frequent emicizumab regimens for...
Treatment with anagrelide was associated with prolonged responses in patients with essential thrombocythemia (ET), according to results of a long-term observational, retrospective study reported in the British Journal of Haematology.[1] Anagrelide is an oral imidazo-quinazoline compound that was approved in 1997 by the US Food and Drug Administration (FDA) to reduce platelet...
BUFFALO, NY- February 7, 2024 – A new research perspective was published in Oncotarget’s Volume 15 entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.” In this new paper, researchers Ashley Del Dosso, Elizabeth Tadevosyan, and James R. Berenson from ONCOtherapeutics, Berenson Cancer Center, and...
PERTH, Australia – Lung cancer kills more people globally each year than any other type of cancer, however new Curtin University-led research has found less than five minutes of daily physical activity could be linked with prolonged life in people living with inoperable forms of the disease. The team from...
She is living her life to the fullest, even though she can’t walk or talk. Twelve-year-old Breanna Leatherwood of Tuscaloosa is one of about 50 females in Alabama known to have Rett syndrome, a neuro- developmental disorder that affects a gene on the X chromosome and occurs almost exclusively in...
SHANGHAI, China and SOUTH SAN FRANCISCO, Calif. — Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in...
SHANGHAI, China — Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by South Korean’s Ministry of Food and Drug Safety (MFDS) for the treatment of primary...
SHANGHAI, China — Everest Medicines a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration (TFDA) for the treatment of primary immunoglobulin A...
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each worth $5,000, to cover a winning applicant’s...